Rational development of an mRNA antibody cocktail with extended therapeutic window against ricin intoxication Authors: Mei Wu, Xi Luo, Pei-Yu Jiang, Qian Xu, Fei-Xue Du, Xiang Chen, Feng-Qin Yang, Zi-Jin Cui, Yu-Yan Li, Jie-Yu Chen, Tian-Shu Cao, Jing-Lin Wang, Wen-Wen Xin, Qing Ye, Cheng-Feng Qin Published: 2026 ABSTRACT AbstractRicin, a highly toxic protein derived from Ricinus communis, is recognized as a biological threat due to its high toxicity and the absence of approved specific antidotes. Monoclonal antibodies (mAbs) represent an emergency therapeutic for ricin intoxication. However, the short therapeutic window of existing antibody administration significantly limits their effectiveness in post-exposure treatment. To address these limitations, we developed a novel strategy leveraging lipid nanoparticle (LNP) encapsulated-mRNA platform for toxin antibodies delivery in vivo, enabling a time-saving, cost-effective approach that extends the therapeutic window. We designed and characterized two mRNA-encoded antibodies targeting the A chain (RTA) and B chain (RTB) of ricin, termed mRNA-43RCA and mRNA-Sy1H3, respectively. Then, each LNP-encapsulated mRNA antibody was combined to formulate the final mRNA antibody cocktail, termed mRNA-cocktail-LNP. In vivo studies demonstrated that a single administration of mRNA-cocktail-LNP enabled the rapid production of neutralizing antibodies, which conferred protection in mice against a subsequent lethal-dose ricin challenge. Additionally, mRNA-cocktail-LNP exhibited a significantly extended circulating half-life compared to its protein-format antibody in mice, and a single prophylactic dose provided complete protection against lethal ricin challenge for at least 14 days post administration. More importantly, mRNA-cocktail-LNP conferred protection even when administered 10 h after lethal-dose ricin exposure, demonstrating an extended therapeutic window. Taken together, our results indicate that mRNA-cocktail-LNP represents a promising therapeutic candidate against ricin intoxication, highlighting the potential of mRNA-LNP platform as a universal strategy for developing antibody-based countermeasures against ricin and a broad spectrum of other biological threats.Key points• An mRNA antibody cocktail (mRNA-cocktail-LNP) was designed to against RT and protect the mice from challenge with ricin both prophylactic and post-exposure treatments• mRNA-cocktail-LNP with a prolonged half-life compared to its protein format.• mRNA-cocktail-LNP significantly extended the limited therapeutic window to 10 h for ricin intoxication treatment.Supplementary InformationThe online version contains supplementary material available at 10.1007/s00253-026-13893-z. Introduction Ricin (RT), a natural plant toxin derived from the seeds of Ricinus communis, is a ribosome-inactivating protein (RIP) due to its ability to irreversibly inhibit protein synthesis (Bolognesi et al. 2016). It is classified as a chemical/biological warfare agent under both the chemical weapons convention (CWC) and the biological weapons convention (BWC). Exposure to ricin can occur via different routes. The ingestion of ricin can cause toxin-induced multiple organ failure, which leads to death (Abbes et al. 2021), and exposure to ricin via injection causes nausea, vomiting, muscular pain, and progress multiple organ failure results in death (Bucaretchi et al. 2021; Coopman et al. 2009). Furthermore, the widespread accessibility of Ricinus communis seeds and relative simplicity of ricin extraction have contributed to its intoxication in accident or bioterrorism incidents, possessing a great threat to public safety (Abbes et al. 2021; Berger et al. 2016; Bozza et al. 2015). To date, various therapeutics, including small-molecule inhibitors and vaccines, have been developed and evaluated for efficacy against ricin intoxication in preclinical studies (Stechmann et al. 2010; Zhao et al. 2020). Among these, antibody-based therapy remains one of the most specific and effective treatment strategies available. However, the timing of antibody administration is critical to the therapeutic outcomes after ricin intoxication, as intervention must occur within the therapeutic window to ensure effective protection. Preclinical studies have shown that antibody treatment at the same time as ricin poisoning or two hours post intoxication failed to provide complete protection in mice (Orsini Delgado et al. 2021; Van Slyke et al. 2016). Therefore, the development of antibodies with extended therapeutic window is urgently required to effectively address the threat of ricin exposure. Recent advances in messenger RNA (mRNA)-based therapeutics have demonstrated significant potential in addressing infectious diseases (Arevalo et al. 2022; Zhang et al. 2020; Zuiani et al. 2024). To date, mRNA vaccines against SARS-CoV-2 and its variants, RSV, have been approved for clinical use (Baden et al. 2021; FDA 2023, 2025a, 2025b; Polack et al. 2020). Meanwhile, mRNA-based antibodies against SARS-CoV-2, MPXV and chikungunya virus have been well developed with promising efficacy in preclinical and clinical trials (August et al. 2021). However, mRNA-based antibodies against ricin have not been described to date. mRNA-based antibody utilizes host endogenous translational machinery to enable rapid and sustained expression of high levels of properly modified and functional antibodies, and has been demonstrated to possess a longer half-life compared to traditional antibodies in vivo (Deng et al. 2022; Wang et al. 2024; Zhao et al. 2023), possessing a potential to extend the therapeutic window after exposure to ricin. Additionally, intracellular expression of antibodies could neutralize the toxins that have entered the cytosol and prevent their subsequent cytotoxic effects (Czajka et al. 2022; O'Hara and Mantis 2013). In this study, we developed and characterized an mRNA antibody cocktail (mRNA-cocktail-LNP) against ricin based on two monoclonal antibodies targeting RTA and RTB, respectively, using our well-established and validated mRNA-LNP platform (Zhang et al. 2020; Zhao et al. 2021). Further experiments clearly demonstrated that a single-dose administration of mRNA-cocktail-LNP rapidly induces neutralizing antibodies in mice, providing sustained protection and post-exposure therapy against ricin intoxication. More importantly, mRNA-cocktail-LNP significantly extended the limited therapeutic window to 10 h for ricin intoxication treatment, which is of great significance in handling the threat of ricin. Materials and methods Cells Vero cells, Huh7 cells, BHK-21, and HEK293T cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM), supplemented with 10% fetal bovine serum (FBS), 10 mM HEPES, and 1% penicillin/streptomycin. mRNA preparation Plasmids encoding the human IgK light-chain signal peptide and the codon-optimized HC and LC of two anti-ricin antibodies were synthesized by GENEWIZ (Suzhou, China). mRNAs were then produced in vitro by using T7 high-yield RNA transcription kit (DD4201, Vazyme) from the linearized DNA plasmids. A Cap-1 structure was added to the 5′ end of mRNAs by using Vaccinia Capping Enzyme (DD4109, Vazyme), and Cap-2′-Methyltransferase (DD4110, Vazyme). Evaluation of mRNAs expression in vitro BHK-21 cells, Huh7 cells, and HEK293T cells were seeded in 12-well plates and cultured at 37 ℃ in 5% CO2 for 12 h. mRNAs encoding HC and LC (at the molar ratio of 1:1) were transfected into cells using Lipofectamine MessengerMAX Reagent (LMRNA015, Thermo Fisher Scientific) according to the manufacturer’s instruction. Supernatants were harvested at 24 h post transfection. Supernatants were respectively mixed with 5 × native loading (nonreducing) and 5 × SDS loading for antibody expression analysis. The samples were then loaded for SDS-PAGE. The samples without reduction were detected by western blot using HRP-conjugated goat anti-human IgG-Fc (ZB-2304, ZSBiO) at 1:5000 for secreted antibody detection. The reduced samples were detected by western blot using HRP-conjugated goat anti-human IgG-Fc (ZSBiO) at 1:5000 and HRP-conjugated goat anti-human F(ab′)2 (ab98535, abcam) at 1:10,000 for HC and LC of antibody analysis. All blots derive from the same experiment and are processed in parallel. Immunofluorescent assay For immunofluorescence staining, HEK293T cells were seeded in 12-well plates at 37 °C in 5% CO2. Twelve hours later, mRNAs encoding HC and LC of antibody were transfected into HEK293T cells using Lipofectamine MessengerMAX Reagent (Thermo Fisher Scientific). Transfected cells were fixed with methanol/acetone (7:3) 24 h post-transfection and blocked with 5% bovine serum albumin at 37 °C for 1 h, and then incubated with antibody conjugated to Fluorescein-conjugated antibody (SA00013-2, 1:500, Proteintech). After being washed with PBS three times, the cell nuclei were stained with DAPI (MBD0015, 1:1000, Sigma). Antibody-positive cells were examined using fluorescence microscope (Zeiss). Ricin-specific antibody detection Ricin-specific IgG antibody titers were evaluated by ELISA. Full-length RT was coated onto flat-bottom, high-binding, 96-well plates at 100 ng per well and incubated at 4 °C overnight. Plates were washed five times with PBS containing 0.1% Tween 20 (PBST) and blocked with PBS containing 5% nonfat milk for 1 h at 37 °C. Then plates were washed and supernatants were added to blocked plates and incubated for 1 h at 37 °C. After five times washed, the secondary antibody HRP-conjugated goat anti-human IgG-Fc (ZB-2304, ZSBiO) at a dilution of 1:5000 was added to each well. After 1 h of incubation at 37 ℃, the plates were washed five times. Then, the substrate reagent was added and incubated for 15 min at 37 ℃ before being quenched with stop solution. The OD value at 450/630 nm was measured using Synergy H1 hybrid multimode microplate reader (BioTek). ELISA for evaluation of antibody expression The concentration of antibodies was detected using the commercial human IgG ELISA kit (D711074-0096, Sangon Biotech) according to the manufacturer’s instructions. Briefly, standards and diluted samples were respectively added to the pre-coated 96-well plate and incubated for 90 min at 37 °C. Then the biotin-conjugated antibody working solution was added and incubated for 1 h at 37 °C. After five times washing, the HRP-conjugated streptavidin working solution was added and incubated for 30 min at 37 °C. After five times washing, chromogen reagent was added to the plate and incubated at 37 °C for about 15 min before being quenched with stop solution. Plates were read using Synergy H1 hybrid multimode microplate reader (BioTek) at 450/630 nm. Cell viability-based neutralization assay The neutralizing activity were tested using a cell-based viability assay. In brief, Vero cells were seeded in 96-well plates and cultured at 37 ℃ for 12 h. Serial twofold diluted samples were incubated 4 EC50 of the ricin for 1 h at 37 ℃. Then the mixtures were removed to the cultured cells and cultured 24 h at 37 ℃. CCK-8 regent was added to the each well followed by incubation for 1 h at 37 ℃. The optical density at the wavelength of 450 nm and 630 nm were measured using Synergy H1 hybrid multimode microplate reader (BioTek). Wells containing cells without ricin were used as controls to determine the 100% viability. The 50% neutralization titer (NT50) was defined as the sample dilution at which the cell viability was 50% compared with the control wells. The NT50 was determined by non-linear regression. Lipid-nanoparticle encapsulation of the mRNA LNP formulations were prepared using an established procedure as previously described (Zhang et al. 2020). Briefly, the HC and LC encoding mRNAs were mixed at a molar ratio of 1:1 for two antibodies. The lipid mixture including ionizable lipids, 1-,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), cholesterol, and PEG-lipid was combined with mRNA working solution at a ratio of 1:2 through a T-mixer. The formulation was then diafiltrated in 10 × volume of PBS (pH 7.4), reduced to the desired concentrations, and filtrated with a 0.22 µm filter. The final mRNA-LNP formations (termed mRNA-43RCA-LNP and mRNA-Sy1H3-LNP) were stored at 2–8 °C until use (Chen et al. 2022; Hannawi et al. 2024; Zhang et al. 2020; Zhao et al. 2021). The particle size, distribution, and concentration were tested as described previously. The combined mRNA antibody candidate (termed mRNA-cocktail-LNP) was developed by mixing mRNA-43RCA-LNP and mRNA-Sy1H3-LNP under the same LNP-mRNA vaccine platform. Encapsulation efficiency of the mRNA-LNP The encapsulation efficiency of mRNA-LNP was determined using Quant-iT™ RiboGreen® RNA assay (Thermo Fisher Scientific) as previously described (Zhang et al. 2020; Zhao et al. 2021). Briefly, mRNA-LNP was diluted in TE buffer and TE buffer with 1% Triton X-100 separately. Then the equal volume of RiboGreen was added to the diluted samples. Fluorescence was read using SpectraMax iD3 (Molecular Devices, USA) at 488/525 nm. Encapsulation efficiency was calculated as [1-(RLUuntreated/RLU1% Triton X-100 treated)] × 100%. Prophylactic efficacy of mRNA antibody cocktail in mice All animal experiments were approved by the Experimental Animal Committee of Laboratory Animal Center, AMMS (approval number: IACUC-DWZX-2025-P025). To evaluate the prophylactic efficacy of mRNA-cocktail-LNP in mouse model, groups of 17–19 g female BALB/c mice (n = 5) were intravenously (i.v.) administered with different doses of mRNA-cocktail-LNP (0.1, 0.3 and 1 mg/kg, mpk) or empty LNP as placebo. Before challenge with ricin, all mice’s orbital blood was collected. Blood samples were centrifuged at 8000 r/min for 20 min, and then serum was harvested and subjected to the detection of antibody concentration and neutralization titer as described above. Then, groups of challenged mice (n = 5) were intraperitoneally challenged with 5 × LD50 of ricin 1 day after mRNA-cocktail-LNP injection and monitored daily for survival and body weight. The different tissues of mice were collected at 1 day post challenge for pathological examination. Therapeutic efficiency of mRNA antibody cocktail against ricin To evaluate the therapeutic efficacy of an mRNA antibody cocktail candidate in mice, BALB/c mice (n = 8) were injected intraperitoneally with 2 × LD50 of ricin, and PBS was used as control. Then 0.3 mpk of mRNA-cocktail-LNP was administered to the challenged mice at the indicated time. Body weight and survival were monitored daily for 14 days. Mice of each group (n = 4–5) were euthanized and liver, lung, and spleen were harvested at 1 day post challenge. The analysis of cytokine and chemokines The liver samples from mice were grinded by tissue homogenizer. Then the supernatants were separated and subjected to the cytokines and chemokines detection. The expression of cytokines and chemokines was measured by using a Mouse Cytokine and Chemokine 36-Plex ProcartaPlex 1 A Panel (Thermo Fisher Scientific) according to the manufacturer’s instructions. The data were collected on Luminex 200 and analyzed by Luminex PONENT (Thermo Fisher Scientific). Histopathological analysis For histopathology, partial tissues from mice were fixed in 4% formaldehyde for over 48 h and embedded in paraffin. Sections of the paraffin-embedded tissues were cut and placed on the glass histology slides. Then slides were stained with H&E and examined by the light microscopy. Statistical analysis All data were analyzed using GraphPad Prism 8 (GraphPad Software). Data were shown as the mean ± SEM from at least three independent replicates. Detailed information of statistical analyses was stated in the relevant figure legends. Results Design and characterization of ricin antibody-encoding mRNAs in vitro To develop specific mRNA-encoded antibody cocktail against ricin, we selected the well-characterized single-chain variable fragment (scFv) 43RCA targeting the RTA subunit (Pelat et al. 2009) and an antigen-binding fragment (Fab) Sy1H3 (Yermakova and Mantis 2013) against RTB subunit as core precursors. The constant region encoding mRNAs were then designed and synthesized to generate full-length IgG antibodies, termed mRNA-43RCA and mRNA-Sy1H3, respectively. And the optimized sequences of the antibody-encoding mRNAs are listed in Table S1. Utilizing the well-established mRNA platform, the mRNAs containing necessary elements for efficient translation including 5′ Cap structure, untranslated regions, coding sequences for the heavy-chain (HC) and light (LC) chain of 43RCA and Sy1H3 and a poly(A) tail were prepared as previously described (Zhang et al. 2020) (Fig. 1A).Fig. 1Design and characterization of anti-ricin antibody-encoding mRNAs. A Schematic diagram of the ricin-targeting antibody cocktail and its mRNA format. RTA is drawn as yellow ribbons and RTB as green ribbons. The 43RCA is blue ribbons, and the Sy1H3 is pink ribbons. B The different forms of antibodies expression in HEK293T cell supernatants were determined by Western blotting. HEK293T cells were transfected with HC mRNA and LC mRNA. The supernatants were harvested at 24 h post transfection and detected using a goat anti-human IgG antibody. C Indirect immunofluorescence assay of antibodies expression in HEK293T cells 24 h post-transfection. The mRNA-encoded antibodies were stained in green, and DAPI in blue. Scale bar, 50 µm. D The concentrations of antibodies in mRNA transfection cell supernatants were evaluated using ELISA. HEK293T cells were transfected with HC mRNA and LC mRNA and supernatants were harvested at 24 h post transfection. E The evaluation of binding activity to ricin of the HEK293T cell transfection supernatants using ELISA. F NT50 titers of HEK293T cell supernatants 24 h post-transfection was measured using cell viability-based assay. Data are shown as the mean ± SEM. Statistical differences were analyzed by using one-way ANOVA. *P < 0.05, ***P < 0.001, ****P < 0.0001 Design and characterization of anti-ricin antibody-encoding mRNAs. A Schematic diagram of the ricin-targeting antibody cocktail and its mRNA format. RTA is drawn as yellow ribbons and RTB as green ribbons. The 43RCA is blue ribbons, and the Sy1H3 is pink ribbons. B The different forms of antibodies expression in HEK293T cell supernatants were determined by Western blotting. HEK293T cells were transfected with HC mRNA and LC mRNA. The supernatants were harvested at 24 h post transfection and detected using a goat anti-human IgG antibody. C Indirect immunofluorescence assay of antibodies expression in HEK293T cells 24 h post-transfection. The mRNA-encoded antibodies were stained in green, and DAPI in blue. Scale bar, 50 µm. D The concentrations of antibodies in mRNA transfection cell supernatants were evaluated using ELISA. HEK293T cells were transfected with HC mRNA and LC mRNA and supernatants were harvested at 24 h post transfection. E The evaluation of binding activity to ricin of the HEK293T cell transfection supernatants using ELISA. F NT50 titers of HEK293T cell supernatants 24 h post-transfection was measured using cell viability-based assay. Data are shown as the mean ± SEM. Statistical differences were analyzed by using one-way ANOVA. *P < 0.05, ***P < 0.001, ****P < 0.0001 To evaluate the in vitro expression property of mRNA-43RCA and mRNA-Sy1H3, Western blotting and immunofluorescence assay were performed in mRNA-transfected cells. As expected, full-length antibodies, as well as their HCs and LCs, were detected in supernatants from HEK293T cells at 24 h post transfection (Fig. 1B and Fig. S2). The immunofluorescence assay with human IgG as primary antibodies showed strong positive signals as expected (Fig. 1C). Additionally, a similar expression pattern was also seen in other cells including Huh7 and BHK-21 cells (Fig. S1A, S1B and S2). Next, the two mRNA pairs were 1:1 mixed to produce the corresponding antibody cocktail. The concentrations of produced antibodies in the corresponding mRNA-transfected cell supernatants were determined by human IgG-specific enzyme-linked immunosorbent assay (ELISA), respectively. The total antibody concentrations from the mRNA-cocktail transfected HEK293T cells peaked at 7123 ng/ml at 24 h post transfection (Fig. 1D), and the mRNA-43RCA and mRNA-Sy1H3 transfected cells reached 6887 ng/ml and 1620 ng/ml, respectively. Additionally, high concentrations of antibody were also detected in the antibody-encoding mRNAs transfected Huh7 cells and BHK-21 cells (Fig. S3A and S3B). Further ELISA detection confirmed that the secreted antibodies retained specific binding activity to full-length ricin (Fig. 1E). To further assess whether antibody generated by mRNA was functional, a cell viability-based neutralization assay was performed in Vero cells as previously described (Yermakova and Mantis 2013). As expected, the 50% neutralization titer (NT50) of antibodies produced by mRNA-cocktail, mRNA-43RCA, and mRNA-Sy1H3 approached ~1/22, ~1/11, and ~1/12, respectively. Notably, the neutralizing antibody level of mRNA-cocktail was significantly higher than that of either individual mRNA antibody alone (Fig. 1F). Prophylactic efficiency of mRNA antibody cocktail against ricin intoxication Based on our well-established mRNA-LNP platform (Zhang et al. 2020), mRNA-43RCA and mRNA-Sy1H3 pairs were individually encapsulated into LNPs, termed mRNA-cocktail-LNP (Fig. 2A), for subsequent in vivo assay. The dynamic light-scattering analyses showed that the LNP formulation of mRNA-43RCA and mRNA-Sy1H3 exhibited similar average particle sizes of 88.81 and 84.22 nm, with particle dispersion indices (PDI) less than 0.1 (Fig. S4A and S4B). The encapsulation efficiencies of mRNA-43RCA-LNP and mRNA-Sy1H3-LNP were 97.32% and 97.35%, respectively, as measured by the RiboGreen assay.Fig. 2Prophylactic efficiency of mRNA antibody cocktail against ricin intoxication. A, B Schematic diagram of mRNA-cocktail-LNP (A) and the animal experimental design (B). Groups of mice were administered a single dose of 1 mpk, 0.3 mpk, and 0.1 mpk of mRNA-cocktail-LNP and Placebo. Serum samples were collected at 1 day after administration to antibody detection, and mice were challenged with 5 × LD50 ricin i.p. at 24 h post administration, monitored daily for body weight. Tissues were harvested at 24 h post challenge for histopathological analysis. C Quantification of antibody levels in sera were evaluated using ELISA (n = 5 per group). Sera were collected 1 day after administration. D Ricin neutralization activity was measured by cell viability-based neutralization assay. E Survival curves of mice (n = 5 per group) after lethal ricin challenge. F Weight changes were recorded for 15 days after ricin challenge. G H&E staining of the liver, spleen, and lung from animals administered Placebo or mRNA-cocktail-LNP at a dose of 1 mpk at 24 h post challenge. Scale bar, 50 µm. Data are shown as the mean ± SEM. Statistical differences were analyzed by using two-tailed unpaired t tests. **P < 0.01 Prophylactic efficiency of mRNA antibody cocktail against ricin intoxication. A, B Schematic diagram of mRNA-cocktail-LNP (A) and the animal experimental design (B). Groups of mice were administered a single dose of 1 mpk, 0.3 mpk, and 0.1 mpk of mRNA-cocktail-LNP and Placebo. Serum samples were collected at 1 day after administration to antibody detection, and mice were challenged with 5 × LD50 ricin i.p. at 24 h post administration, monitored daily for body weight. Tissues were harvested at 24 h post challenge for histopathological analysis. C Quantification of antibody levels in sera were evaluated using ELISA (n = 5 per group). Sera were collected 1 day after administration. D Ricin neutralization activity was measured by cell viability-based neutralization assay. E Survival curves of mice (n = 5 per group) after lethal ricin challenge. F Weight changes were recorded for 15 days after ricin challenge. G H&E staining of the liver, spleen, and lung from animals administered Placebo or mRNA-cocktail-LNP at a dose of 1 mpk at 24 h post challenge. Scale bar, 50 µm. Data are shown as the mean ± SEM. Statistical differences were analyzed by using two-tailed unpaired t tests. **P < 0.01 Next, to determine the prophylactic efficacy of our mRNA antibody cocktail, groups of 6–8-week-old BALB/c mice were i.v. injected with varying doses of mRNA-cocktail-LNP followed by lethal ricin challenge via intraperitoneal (i.p.) route (Fig. 2B). Animals receiving empty LNPs served as placebo control. As expected, no antibodies were detected in sera from all mock-treated mice, meanwhile high concentrations of human IgG antibody were detected on day 1 post injection in sera from mRNA-cocktail-LNP-injected mice in a dose-dependent manner (Fig. 2C). Further, neutralization assay showed that all animals that received mRNA-cocktail-LNP injection produced RT-specific neutralizing antibodies, with NT50 of ~1:16, ~1:48, and ~1:80, respectively. Following ricin challenge, all animals that received placebo injected died within 2 days (Fig. 2E). Remarkably, all mice administered with high and middle doses (1 and 0.3 mpk) survived and even the low dose (0.1 mpk) of mRNA-cocktail-LNP conferred protection in 40% (2/5) animals (Fig. 2E). In addition, daily body weight also showed similar protection efficacy of mRNA-cocktail-LNP in dose-dependent manner (Fig. 2F). Additionally, histopathological analysis of liver, spleen, and lung tissues from all challenged mice were collected on day 1 post challenge. As expected, severe pathologic damages were observed in all placebo-injected animals, Kupffer cells proliferation and inflammatory cells infiltration were seen in liver, disintegration of splenic follicles, loss of trabecular definition and accumulation of lipofuscin in spleen, alveolar septal thickening, alveolar atrophy and massive inflammatory cell infiltration in lung tissues and elevated histopathological scores (Fig. S4). In contrast, no obvious pathological changes were seen in all animals received mRNA-cocktail-LNP treatment at a dose of 1 mpk (Fig. 2G). Collectively, these results demonstrated that a single injection mRNA-cocktail-LNP effectively protect mice from lethal challenge of ricin. mRNA-cocktail-LNP possesses a more favorable pharmacokinetic profile and prolonged prophylactic efficacy compared to the protein-format cocktail To investigate the pharmacokinetic profile of mRNA-cocktail-LNP in vivo, groups of 6- to 8-week-old female mice received a single administration of either 1 mpk of mRNA-cocktail-LNP, or equal dose of cocktail antibody in protein format, and serum samples were collected at indicated time for antibody concentrations detection. As shown in Fig. 3A, sera antibody concentrations peaked at 6 h with a mean concentration of 55.18 µg/ml and then decreased rapidly, with an average half-life of 0.97 days. In contrast, mRNA-cocktail-LNP administration resulted in a higher antibody concentration (78.75 µg/ml) at 6 h post injection and peaked with a mean value of 116.91 µg/ml at 14 h post administration, followed by a gradual decline (Fig. 3A). Notably, the sera antibody concentrations remained at 17.76 µg/ml even 14 days after administration of mRNA-cocktail-LNP. The mean residence time (MRT) and its half-life (t1/2) were calculated to 5.26 and 8.43 days, respectively. As a result, the mean AUClast and AUCIFN reached 748.12 and 1128.27 day × µg/ml, respectively (Table. S2). These results suggested a potential long-term prophylactic efficacy conferred by mRNA-cocktail-LNP.Fig. 3mRNA-cocktail-LNP provides a long-term protection against ricin challenge in mice. A The antibody concentrations of sera in mice were measured by ELISA. Briefly, groups of 6–8-week-old mice (n = 5 per group) were i.v. administrated with a single dose of 1 mpk of cocktail and mRNA-cocktail-LNP, respectively. At indicated times post administration, sera of mice were measured by ELISA. B Schematic of animal experimental design. Groups of mice (n = 5-8 per group) were administered with cocktail or mRNA-cocktail-LNP and challenged with 2 × LD50 ricin after 14 days administration, and monitored daily for body weight. C Survival curve of mice after ricin challenge. Statistical differences were analyzed by using Wilcoxon log-rank survival test. ns. not significant, **P < 0.0021, ***P < 0.0002. D Weight changes were recorded for 14 days after ricin challenge. Data are shown as the mean ± SEM mRNA-cocktail-LNP provides a long-term protection against ricin challenge in mice. A The antibody concentrations of sera in mice were measured by ELISA. Briefly, groups of 6–8-week-old mice (n = 5 per group) were i.v. administrated with a single dose of 1 mpk of cocktail and mRNA-cocktail-LNP, respectively. At indicated times post administration, sera of mice were measured by ELISA. B Schematic of animal experimental design. Groups of mice (n = 5-8 per group) were administered with cocktail or mRNA-cocktail-LNP and challenged with 2 × LD50 ricin after 14 days administration, and monitored daily for body weight. C Survival curve of mice after ricin challenge. Statistical differences were analyzed by using Wilcoxon log-rank survival test. ns. not significant, **P < 0.0021, ***P < 0.0002. D Weight changes were recorded for 14 days after ricin challenge. Data are shown as the mean ± SEM Based on results described above, we further assessed the long-term prophylactic efficacy of mRNA-cocktail-LNP in comparison with the protein antibody-format. Groups of BALB/c mice were administered with cocktail or mRNA-cocktail-LNP, and then challenged with a lethal dose of ricin at 14 days post administration (Fig. 3B). All mice that received empty LNP died within 4 days. In contrast, 100% survival was observed in the mRNA-cocktail-LNP treated group, and 25% of those administered cocktail survived during the observation period (Fig. 3C). Besides, an obvious weight loss was observed in both cocktail and empty LNP treated groups, whereas mice administered with mRNA-cocktail-LNP maintained relatively stable body weight (Fig. 3D). Overall, our results clearly demonstrated that mRNA-cocktail-LNP provided a long-term prophylactic efficacy against lethal ricin challenge. Therapeutic efficiency of mRNA antibody cocktail against ricin intoxication We further evaluated whether the mRNA-based antibody administration exhibits a therapeutic effect following ricin intoxication. Briefly, groups of mice were challenged with a lethal dose of ricin, with one group serving as control without any treatment. Then the ricin-challenged mice received mRNA-cocktail-LNP or empty LNPs at the indicated time points post challenge (Fig. 4A). All mice administered with empty LNP died within 1 week. In contrast, 100% of mice that received the mRNA antibody cocktail within 4 h post challenge survived. 80% survival was observed in the group treated at 6 h post challenge. There are 20% of mice treated with mRNA-cocktail-LNP survived even when the formulation was injected 10 h post challenge (Fig. 4B). Besides, placebo-treated mice exhibited rapid weight loss, whereas those surviving mice in the treatment group showed only transient weight reduction and subsequently regained weight during the later stage of observation (Fig. 4C). Additionally, as previously described, ricin intoxication resulted in an aggravated pathological change in the liver, spleen and lung of placebo-treated mice. In contrast, the mice administered mRNA-cocktail-LNP at 2 h post challenge exhibited no significant pathological damage and normalized histopathological scores (Fig. 4D and Fig. S5). Furthermore, an increased level of cytokine and chemokine expression was detected in liver samples from mice without any treatment after challenge by Luminex analysis (Fig. 4E). Notably, the mRNA antibody-treated mice exhibited a lower concentration of most cytokines and chemokines after challenge, especially TNF-α and IL-6 (Fig. 4E-G), indicating that the mRNA-based antibody cocktail effectively reduces proinflammatory cytokines and confers protective efficacy after ricin intoxication.Fig. 4Therapeutic efficiency of the mRNA-cocktail-LNP in mouse model. A Schematic of animal experimental design. Groups of mice were i.p. challenged with 2 × LD50 ricin and administered with mRNA-cocktail-LNP at a dose of 0.3 mpk at the indicated time, monitored daily for body weight. Tissues were harvested at 24 h post challenge. B Survival curves of mice (n = 7-8 per group) after ricin challenge. Statistical differences were analyzed by using Wilcoxon log-rank survival test. ns. not significant, *P < 0.0332, ****P < 0.0001. C Weight changes were recorded for 14 days after ricin challenge. D Histopathologic analysis of the liver, spleen and lung from animals received at 24 h post challenge. Scale bar, 50 µm. E Liver tissue cytokine and chemokine analyses were determined by Luminex and are presented as fold changes compared to Control (n = 4–5 per group). F, G The concentrations of cytokines and chemokines in liver samples collected 24 h post challenge. Data are shown as the mean ± SEM. Statistical differences were analyzed by using one-way ANOVA. *P < 0.1 Therapeutic efficiency of the mRNA-cocktail-LNP in mouse model. A Schematic of animal experimental design. Groups of mice were i.p. challenged with 2 × LD50 ricin and administered with mRNA-cocktail-LNP at a dose of 0.3 mpk at the indicated time, monitored daily for body weight. Tissues were harvested at 24 h post challenge. B Survival curves of mice (n = 7-8 per group) after ricin challenge. Statistical differences were analyzed by using Wilcoxon log-rank survival test. ns. not significant, *P < 0.0332, ****P < 0.0001. C Weight changes were recorded for 14 days after ricin challenge. D Histopathologic analysis of the liver, spleen and lung from animals received at 24 h post challenge. Scale bar, 50 µm. E Liver tissue cytokine and chemokine analyses were determined by Luminex and are presented as fold changes compared to Control (n = 4–5 per group). F, G The concentrations of cytokines and chemokines in liver samples collected 24 h post challenge. Data are shown as the mean ± SEM. Statistical differences were analyzed by using one-way ANOVA. *P < 0.1 Discussion Ricin, a highly toxic protein with a wide range of sources, possesses a significant threat to public safety and has been biologically weaponized. The development of effective countermeasures is of great significance for preventing both deliberate acts of terrorist attacks and accidental ricin intoxication. Based on traditional antibody therapy, the development of novel antibody therapy has also been actively explored. Previously, a DNA-monoclonal antibody targeting RTA has been reported as a treatment strategy to counter ricin via intramuscular electroporation (IM EP) (Yu et al. 2023). Moreover, Yu and his colleagues developed a novel strategy using adeno-associated virus (AAV) gene transfer to achieve prolonged systemic serum levels of neutralizing antibody against ricin (Yu et al. 2025). Herein, we developed an antibody cocktail based on mRNA-LNP platform to combat ricin. The results showed that mRNA-cocktail-LNP possesses a superior pharmacokinetic profile compared to its protein format. The half-life of mRNA-cocktail-LNP lasts for up to 8.43 days, which is much longer than that of protein format. In contrast to protein-based antibodies, which lose protective efficacy when given more than 2 h post-exposure (Van Slyke et al. 2016), our mRNA-cocktail-LNP still provided 20% survival even when administered at 10 h after lethal ricin challenge. Moreover, while DNA-based antibodies only offer prophylactic protection within 5 days post administration (Yu et al. 2023), mRNA-cocktail-LNP provides full prophylactic protection for at least 14 days. Together, these data demonstrate that our mRNA antibody platform achieves a substantially extended therapeutic and prophylactic window over both protein- and DNA-based approaches. Following ricin exposure, the toxin rapidly enters host cells and exerts potent cytotoxicity. The rapid intracellular expression of antibodies encoded by mRNA-cocktail-LNP enables direct neutralization of ricin that has already entered the cytosol, which helps reduce cellular damage and improve therapeutic outcomes. Moreover, the prolonged systemic circulation and extended half-life of mRNA-encoded antibodies likely contribute synergistically to the significantly expanded therapeutic window. However, the exact mechanism and relative contribution of intracellular neutralization remain to be further investigated in future studies. Additionally, many studies showed that the antibody cocktail targeting both RTA and RTB exhibited a more favorable neutralizing activity and protection efficiency (Rong et al. 2020a; Rong et al. 2020b). Consistently, the results in our research demonstrated that the mRNA antibody cocktail exhibited a superior neutralizing antibody titer than that of either individual mRNA antibody in vitro. The animal experiments suggested a single-dose administration of mRNA-cocktail-LNP successfully elicited high-level expression of neutralizing antibodies and protected the mice from lethal ricin challenge. However, the different concentration of antibodies expressed by mRNA-43RCA and mRNA-Sy1H3 was observed. Further fine-tuning the ratio according to the actual antibody expression levels of 43RCA and Sy1H3 will likely further improve protective efficacy. Exposure to ricin can occur via oral ingestion, inhalation, or intramuscular penetration, though the manifestation and severity of poisoning vary markedly with the exposure route. Regardless of the exposure route, ricin intoxication results in systemic response characterized by multi-organ pathological lesions, especially in the lung and spleen (Benson et al. 2011; Pincus et al. 2015; Sapoznikov et al. 2021, 2019). Our data suggested the mRNA-cocktail-LNP treatment effectively mitigated ricin-induced organ damage in liver, lung and spleen. A previous study developed an apparatus that achieved the antibody nebulization administration in Macaques against ricin (Respaud et al. 2016). Furthermore, the field has acquired extensive development of LNP platforms designed for extrahepatic delivery, including spleen and lung (Meshanni et al. 2025; Xue et al. 2025; Yin et al. 2025; Zhang et al. 2025). It is worthwhile to further explore delivering antibody-encoding mRNAs to ricin receptor-enriched tissues and reduce the severity of ricin-induced pathological damage. Meanwhile, further evaluation of the protective efficacy of the mRNA-cocktail-LNP using other challenge routes is also of great importance. Additionally, the pharmacodynamics of mRNA-cocktail-LNP warrant systematic evaluation, and its long-term expression level beyond 14 days as well as the therapeutic window remain to be further explored. In conclusion, our preclinical study developed an mRNA-cocktail-LNP with a prolonged half-life compared to its protein format, which was proven to efficiently protect the mice from challenge with a lethal dose of ricin and extended the window for both prophylactic and post-exposure treatment. The potent advantages of mRNA-cocktail-LNP make it a promising antibody candidate against ricin for further study. Supplementary Information Below is the link to the electronic supplementary material.ESM 1(DOCX 779 KB) (DOCX 779 KB)